

Development of a novel small-molecule therapeutic candidate YH34180A for Chronic Kidney Disease

Yuhan Corporation



OTHERS	Preclinical
Product Type	Small molecule
Indication	Chronic Kidney disease (CKD)
Target	Inflammation-related target (undisclosed)
MoA(Mechanism of Action)	Suppression of inflammation and fibrosis through modulation of inflammatory cell recruitment and fibrotic signaling pathways
Competitiveness	<ul style="list-style-type: none"> • First-in-class small-molecule inhibitor directly targeting core inflammatory and fibrotic pathways in CKD • Superior preclinical efficacy compared to approved therapies and potential for additive benefit in combination settings • High target selectivity with minimal risk of CNS-related toxicity • Availability of plasma PD biomarkers enabling quantitative monitoring of treatment response
Development Stage	Preclinical
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.